Pinatuzumab vedotin: Difference between revisions

Latest revision as of 11:05, 15 February 2025

Pinatuzumab Vedotin[edit]

Pinatuzumab vedotin is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. It is a targeted therapy that combines a monoclonal antibody with a cytotoxic agent, specifically designed to deliver the drug directly to cancer cells, thereby minimizing damage to normal cells.

Mechanism of Action[edit]

Pinatuzumab vedotin consists of a monoclonal antibody that targets the CD22 antigen, which is commonly expressed on the surface of B-cell malignancies. The antibody is linked to a cytotoxic agent, monomethyl auristatin E (MMAE), via a protease-cleavable linker. Once the ADC binds to the CD22 antigen on the surface of a cancer cell, it is internalized and the linker is cleaved, releasing MMAE into the cell. MMAE disrupts the microtubule network, leading to cell cycle arrest and apoptosis.

Clinical Development[edit]

Pinatuzumab vedotin has been evaluated in clinical trials for the treatment of non-Hodgkin lymphoma (NHL), particularly in patients with relapsed or refractory disease. The ADC has shown promise in targeting CD22-positive B-cell malignancies, offering a potential therapeutic option for patients who have exhausted other treatments.

Side Effects[edit]

As with many cancer therapies, pinatuzumab vedotin can cause a range of side effects. Common adverse effects include peripheral neuropathy, fatigue, nausea, and myelosuppression. The severity of side effects can vary depending on the dosage and the individual patient's response to the treatment.

Future Directions[edit]

Research is ongoing to explore the full potential of pinatuzumab vedotin in combination with other therapies, as well as its efficacy in different subtypes of B-cell malignancies. The development of ADCs like pinatuzumab vedotin represents a significant advancement in the field of targeted cancer therapy, offering hope for more effective and less toxic treatment options.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Pinatuzumab vedotin''' is an [[antibody-drug conjugate]] designed for the treatment of [[cancer]]. It is composed of an [[antibody]] (pinatuzumab) linked to a [[cytotoxic]] agent (vedotin). The antibody targets [[CD22]], a protein commonly found on [[B cells]], and delivers the cytotoxic agent to these cells, causing their death.
+== Pinatuzumab Vedotin ==
-== Development ==
+[[File:Vedotin_ADCs.svg|thumb|right|Diagram of Vedotin Antibody-Drug Conjugates]]
-Pinatuzumab vedotin was developed by [[Genentech]], a member of the [[Roche Group]]. It was granted [[orphan drug]] status by the [[Food and Drug Administration]] (FDA) in 2014 for the treatment of [[diffuse large B-cell lymphoma]] (DLBCL) and [[indolent non-Hodgkin lymphoma]] (iNHL).
-== Clinical trials ==
+'''Pinatuzumab vedotin''' is an [[antibody-drug conjugate]] (ADC) designed for the treatment of certain types of [[cancer]]. It is a targeted therapy that combines a [[monoclonal antibody]] with a cytotoxic agent, specifically designed to deliver the drug directly to cancer cells, thereby minimizing damage to normal cells.
-Several [[clinical trial]]s have been conducted to evaluate the safety and efficacy of pinatuzumab vedotin. In a phase II study, the drug showed promising results in patients with relapsed or refractory DLBCL and iNHL. However, further development of the drug was discontinued in 2016 due to unfavorable risk-benefit profile.
-== Mechanism of action ==
+=== Mechanism of Action ===
-Pinatuzumab vedotin works by binding to CD22 on the surface of B cells. Once bound, the drug is internalized and the cytotoxic agent is released, causing cell death. The specificity of the antibody for CD22 allows for targeted delivery of the cytotoxic agent, minimizing damage to healthy cells.
-== Side effects ==
+Pinatuzumab vedotin consists of a monoclonal antibody that targets the [[CD22]] antigen, which is commonly expressed on the surface of [[B-cell]] malignancies. The antibody is linked to a cytotoxic agent, [[monomethyl auristatin E]] (MMAE), via a protease-cleavable linker. Once the ADC binds to the CD22 antigen on the surface of a cancer cell, it is internalized and the linker is cleaved, releasing MMAE into the cell. MMAE disrupts the [[microtubule]] network, leading to cell cycle arrest and apoptosis.
-Common side effects of pinatuzumab vedotin include [[fatigue]], [[nausea]], [[diarrhea]], and [[fever]]. Serious side effects can include [[neutropenia]], [[thrombocytopenia]], and [[anemia]].
-== See also ==
+=== Clinical Development ===
+Pinatuzumab vedotin has been evaluated in clinical trials for the treatment of [[non-Hodgkin lymphoma]] (NHL), particularly in patients with relapsed or refractory disease. The ADC has shown promise in targeting CD22-positive B-cell malignancies, offering a potential therapeutic option for patients who have exhausted other treatments.
+=== Side Effects ===
+As with many cancer therapies, pinatuzumab vedotin can cause a range of side effects. Common adverse effects include [[peripheral neuropathy]], fatigue, nausea, and [[myelosuppression]]. The severity of side effects can vary depending on the dosage and the individual patient's response to the treatment.
+=== Future Directions ===
+Research is ongoing to explore the full potential of pinatuzumab vedotin in combination with other therapies, as well as its efficacy in different subtypes of B-cell malignancies. The development of ADCs like pinatuzumab vedotin represents a significant advancement in the field of targeted cancer therapy, offering hope for more effective and less toxic treatment options.
+== Related Pages ==
 * [[Antibody-drug conjugate]]
+* [[Monoclonal antibody]]
+* [[Non-Hodgkin lymphoma]]
 * [[CD22]]
-* [[Diffuse large B-cell lymphoma]]
+* [[Microtubule]]
-* [[Indolent non-Hodgkin lymphoma]]
 [[Category:Antibody-drug conjugates]]
 [[Category:Cancer treatments]]
-[[Category:Orphan drugs]]
-{{stub}}